The industry urgently requires integrated solutions to overcome bottlenecks like HAMA response, complex chain mismatches, and lengthy empirical optimization cycles. In this session, Cyagen unveils a paradigm shift: an integrated "AI-assisted, fully human" antibody discovery platform workflow. We will explore how the HUGO-Ab™ franchise generates high-affinity, fully human antibodies in vivo, effectively eliminating traditional humanization and affinity maturation steps. Furthermore, we will demonstrate how the AbSeek™ AI engine leverages proprietary algorithms to provide high-accuracy predictions for pairing and developability. By merging biological fidelity with computational intelligence, this dual-drive strategy transforms antibody discovery into a process of data-driven precision, enabling the discovery of candidates with superior developability and faster clinical entry.